Other

Eyegene Inc.

Mogam Biotechnology Research Institute

Bio Clue & Solutions Co, Ltd.

Bio Clue & Solution Co., Ltd.

Kwon, Hyung-joo

Kim, Tae-yoon

Shin, Dong-heon

Doo-Sik Kim

Kwang-Hoe Chung

Tae-yoon Kim

Hyung-Joo Kwon

Yang-Je Cho

Jin-Wook Jang

Oh-Woong Kwon

Won-Il Yoo

Hyun-Ju Doh

Hyeong-Joon Lim

Soo-Mee Kwon

You-Seok Koh

Hong-Mo Moon

Yung-Dae Yun

Jae-Hoon Hwang

Chin-Kyu Huh

Yang-Soo Jang

Sung-Yu Hong

Dong-Heon Shin

Young-Doug Sohn

Weon-Kyoo You

Kwang Hoe Chung

In-Cheol Kang

Yang-Soon Kim

A method for treating a vascular-related disease in a subject in need thereof, includes administering to the subject a peptide having a sequence Xaa-Gly-Asp. The peptide may have a sequence of SEQ ID NOS: 1, 2, 4, 6 to 10. The vascular-related disease may be edema and/or ischemia caused by blood leakage of blood vessel walls, damages of blood vessels or abnormal angiogenesis.

Method for treating vascular-related disease

Disclosed are a monoclonal antibody against human D-dimer produced in a mouse and high molecular weight cross-linked fibrin including a corresponding epitope, a cell line secreting the monoclonal antibody, and methods for producing the same. The anti-D-dimer monoclonal antibody of the present invention may be effectively used as a diagnosis agent for screening and detecting in-vivo D-dimer, and high molecular weight cross-linked fibrin and its derivatives containing the D-dimer since the monoclonal antibody specifically reacts with D-dimer, and cross-linked fibrin and its derivatives containing the D-dimer, which do not bind to human fibrinogen or fibrin.

Monoclonal antibody against D-dimer and methods of use therefor

Disclosed are a monoclonal antibody against human D-dimer produced in a mouse and high molecular weight cross-linked fibrin including a corresponding epitope, a cell line secreting the monoclonal antibody, and methods for producing the same. The anti-D-dimer monoclonal antibody of the present invention may be effectively used as a diagnotic agent for screening and detecting in-vivo D-dimer, and high molecular weight cross-linked fibrin and its derivatives containing the D-dimer since the monoclonal antibody specifically reacts with D-dimer, and cross-linked fibrin and its derivatives containing the D-dimer, which do not bind to human fibrinogen or fibrin.

Monoclonal antibody against D-dimer and diagnosis agent for detecting D-dimer, crosslinked fibrin and its derivatives containing D-dimer by using the antibody

Disclosed is the therapeutic use of CpG oligodeoxynucleotides for skin diseases. The CpG oligodeoxynucleotides (CpG ODNs) of the present invention show excellent immunoactive effects against skin diseases in both cases of CpG ODNs with a phosphorothioate backbone and CpG ODNs with a phosphodiester backbone.

Therapeutic use of CPG oligodeoxynucleotide for skin disease

Disclosed are oligonucleotides for manipulating an immune reaction. The oligonucleotides of the present invention may be useful to stimulate the immune function, to treat the immune-related diseases and the atopic dermatitis, or to protect the normal immune cells.

[object Object]

The present invention relates to Saxatilin, a protein derived from the venom of a Korean snake,, a process for preparing Saxatilin, and pharmaceutical application of the same as anti-platelet aggregation agent and anti-tumor agent. The present inventors purified Saxatilin from the venom of, cloned its cDNA, and prepared recombinant Saxatilin by culturing a microorganism transformed with an expression vector containing the cDNA. Saxatilin effectively suppresses the platelet aggregation and angiogenesis of tumor cells, which makes possible its practical application as an active ingredient of anti-platelet agent and anti-tumor agent.

The present invention relates to an anti-tumor agent comprising Salmosin which is a novel disintegrin containing Arg-Gly-Asp (RGD) sequence and derived from venom of Korean snake, as an active ingredient. Salmosin is a disintegrin which blocks the function of &agr;v&bgr;3 integrin and strongly inhibits tumor angiogenesis, tumor metastasis as well as growth of solid tumor. Salmosin does not exhibit cytotoxicity within an effective dose range where tumor growth is efficiently suppressed without any untoward effect on preexisting blood vessels and normal angiogenesis. Accordingly, Salmosin can be applied for the development of potent anti-tumor drugs which are effective for various types of cancers.

Anti-tumor agent comprising salmosin as an active ingredient

The present invention relates to a novel cDNA of direct-acting fibrinolytic serine protease ('Salmonase') which is prepared from a Korean viper, Salmosa(Agkistrodon halys brevicaudus), and a direct-acting fibrinolytic serine protease deduced therefrom. The cDNA of direct-acting fibrinolytic serine protease contains 699 nucleotides coding for 233 amino acids, and the Salmonase translated therefrom consists of two subunits of 77 and 156 amino acids, respectively. Salmonase cDNA of the invention may be expressed in the proper systems established in the recombinant E. coli, yeast, baculovirus/insect cells and other animal cells, and the recombinant Salmonase prepared therefrom can be practically applied as an active ingredient of thrombolytic and hemostatic agents.

CDNA of direct-acting fibrinolytic serine protease

Growing community of inventors

Seoul, South Korea

Doo-Sik Kim